SS&C Technologies Holdings, Inc. · SSNC · FY2025 Q4 · Calendar Q1 2026

SS&C reports record Q4 as guidance remains unchanged

SS&C's record Q4, growth in GIDS and GlobeOp, and continued AI and automation investment support a constructive operating outlook; unchanged 2026 guidance and identified healthcare, integration, and license-sale risks temper that view.

Reported After market closeNASDAQTechnology $21.01B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.69 Consensus $1.61
EPS surprise +5.0% Reported versus consensus
Reported revenue $1.65B Consensus $1.62B
Revenue surprise +1.8% Reported versus consensus

Market reaction

event-close to next-session close
Stock move +3.2% Event window
SPY move +1.9% Same window
Abnormal move +1.3% Stock minus SPY
Volume 3.1× Versus trailing sessions
Subsequent drift -3.9% Up to 20 sessions
SSNCSPY benchmark

Ask FN2 about SSNC FY2025 Q4

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The current analysis adds early progress on the Callisto acquisition, the rewritten Amesys/One Health platform, and the Elevance relationship while showing 2026 guidance unchanged from the prior quarter.

Guidance delta

2026 guidance was maintained, targeting about 5% organic growth and a 40% EBITDA margin.

Key takeaways

  • Management described record Q4 performance with double-digit revenue and margin expansion.
  • GIDS, GlobeOp, Black Diamond, and AI-enabled automation were identified as key growth areas.
  • Strong cash flow supports shareholder returns, debt reduction, and continued strategic M&A flexibility.

Management priorities

  • Continue investing in AI and automation across product lines.
  • Expand GlobeOp in Australia and explore additional international markets.
  • Pursue strategic acquisitions while maintaining balance-sheet strength.

Follow SSNC with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
SSNC EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $1.24 Q4 '23 actual $1.26, beat Q1 '24 estimate $1.22 Q1 '24 actual $1.28, beat Q2 '24 estimate $1.20 Q2 '24 actual $1.27, beat Q3 '24 estimate $1.26 Q3 '24 actual $1.29, beat Q2 '25 estimate $1.39 Q2 '25 actual $1.45, beat Q3 '25 estimate $1.47 Q3 '25 actual $1.57, beat Q4 '25 estimate $1.61 Q4 '25 actual $1.69, beat Q1 '26 estimate $1.65 Q1 '26 actual $1.69, beat Q2 '26 estimate $1.68 Q2 '26 actual $1.76, beat Q3 '26 estimate $1.77 Q3 '26 actual $1.78, match Q4 '26 estimate $1.90 Q1 '27 estimate $1.88 Q2 '27 estimate $1.92 Q3 '27 estimate $1.96
Show less

Analyst Consensus ?

ConsensusBuy24 ratings
Bullish1770.8%
Neutral729.2%
Bearish00.0%

Analyst 52W Price Targets

$82.96Current
$65Low
$89.6Average
$115High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
DA Davidson Buy BuyMaintainOct 22, 2026
RBC Capital Outperform OutperformMaintainAug 31, 2026
Needham Buy BuyMaintainJul 24, 2026
JP Morgan Neutral NeutralMaintainJul 20, 2026
Jefferies Buy BuyMaintainJul 20, 2026
Show 19 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $82.96. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
D.A. DavidsonAnalyst unavailable$104$87.09 +25.4%Oct 21, 2026
JefferiesAnalyst unavailable$100$86.92 +20.5%Oct 21, 2026
UBSKevin McVeigh$101$79.29 +21.7%Sep 9, 2026
RBC CapitalAnalyst unavailable$101$83.42 +21.7%Aug 31, 2026
UBSKevin McVeigh$99$80.28 +19.3%Aug 13, 2026
See 33 more

Track every rating change on SSNC the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

SS&C Technologies Holdings, Inc. offers a diverse portfolio of software solutions and related services, catering primarily to the financial services and healthcare industries. The company's sophisticated technology infrastructure spans various critical functions within finance, including securities accounting; front-office capabilities such as trading and financial modeling; middle-office tasks like portfolio oversight and reporting; and comprehensive back-office operations encompassing general accounting, performance measurement, data reconciliation, processing, clearing, regulatory compliance, and tax reporting. In the healthcare sector, SS&C provides specialized solutions for claims adjudication, benefits administration, care management, and business intelligence. These offerings are instrumental in helping professionals in both domains automate intricate business processes and efficiently handle their extensive information processing demands.…

Historical context

All SSNC earnings

Technology peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the SSNC recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-24T00:20:42.311683+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T00:20:42.308600+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.